By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
List view / Grid view
Filter the results
Remdesivir is being prescribed under FDA emergency use authorization as a treatment for patients with COVID-19.
This webinar from Bio-Techne demonstrates how to use a novel in vitro flow cytometry-based assay to monitor SARS-CoV-2 binding to ACE-2.
LifeArc and the Medical Research Council have funded a new drug screening facility that will be established to accelerate COVID-19 drug discovery.
Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
In this article, Ramya Sriram describes how data science is driving innovations in medical biotechnology and genomics.
Study identifies a promising new compound that can open constricted airways and could be a promising treatment for obstructive lung diseases.
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
17 December 2020 | By Living Systems Institute, University of Exeter
Join us live where we explore new methods to improve data quality from high-throughput screens. You'll learn about solutions for common problems in drug-target discovery and our keynote speaker will also look at case studies where new approaches to screening have identified high-quality candidate drugs for proliferative diseases.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.